Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers - 09/01/21
, Stefan Nierkens, PhD b, Edward F. Knol, PhD a, b, Barbara Giovannone, PhD b, Eveline M. Delemarre, MD, PhD b, Jorien van der Schaft, MD, PhD a, Femke van Wijk, PhD b, Marjolein S. de Bruin-Weller, MD, PhD a, Julia Drylewicz, PhD b, ∗, Judith L. Thijs, MD, PhD a, ∗Abstract |
Background |
Atopic dermatitis (AD) is a highly heterogeneous disease, both clinically and biologically, whereas patients are still being treated according to a “one-size-fits-all” approach. Stratification of patients into biomarker-based endotypes is important for future development of personalized therapies.
Objective |
Our aim was to confirm previously defined serum biomarker-based patient clusters in a new cohort of patients with AD.
Methods |
A panel of 143 biomarkers was measured by using Luminex technology in serum samples from 146 patients with severe AD (median Eczema Area and Severity Index = 28.3; interquartile range = 25.2-35.3). Principal components analysis followed by unsupervised k-means cluster analysis of the biomarker data was used to identify patient clusters. A prediction model was built on the basis of a previous cohort to predict the 1 of the 4 previously identified clusters to which the patients of our new cohort would belong.
Results |
Cluster analysis identified 4 serum biomarker–based clusters, 3 of which (clusters B, C, and D) were comparable to the previously identified clusters. Cluster A (33.6%) could be distinguished from the other clusters as being a “skin-homing chemokines/IL-1R1–dominant” cluster, whereas cluster B (18.5%) was a “TH1/TH2/TH17-dominant” cluster, cluster C (18.5%) was a “TH2/TH22/PARC-dominant” cluster, and cluster D (29.5%) was a “TH2/eosinophil-inferior” cluster. Additionally, by using a prediction model based on our previous cohort we accurately assigned the new cohort to the 4 previously identified clusters by including only 10 selected serum biomarkers.
Conclusion |
We confirmed that AD is heterogeneous at the immunopathologic level and identified 4 distinct biomarker-based clusters, 3 of which were comparable with previously identified clusters. Cluster membership could be predicted with a model including 10 serum biomarkers.
Il testo completo di questo articolo è disponibile in PDF.Key words : Atopic dermatitis, endotypes, clusters, biomarkers, prediction, personalized medicine, principal components analysis
Abbreviations used : AD, CsA, EASI, EGF, IQR, PARC, PCA, TARC, TNFSF, TSLP
Mappa
| Research was funded by Regeneron and Sanofi Genzyme Pharmaceuticals, Inc. |
|
| Disclosure of potential conflict of interest: M.S. de Bruin-Weller is a principal investigator and advisory board member for AbbVie and Regeneron Pharmaceuticals, Inc; a principal investigator, advisory board member, and consultant for Sanofi Genzyme; an advisory board member for Eli Lilly and UCB; and a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 1
P. 189-198 - Gennaio 2021 Ritorno al numero
Articolo precedente
- A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps
- Tim Delemarre, Gabriele Holtappels, Natalie De Ruyck, Nan Zhang, Hans Nauwynck, Claus Bachert, Elien Gevaert
- Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis
- Helen He, Robert Bissonnette, Jianni Wu, Aisleen Diaz, Etienne Saint-Cyr Proulx, Catherine Maari, Carolyn Jack, Maudeline Louis, Yeriel Estrada, James G. Krueger, Ning Zhang, Ana B. Pavel, Emma Guttman-Yassky
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?